57th AAAAI. Oligodeoxynucleotides.
This meeting was notable for its eclectic approach to the field of Allergy and Clinical Immunology. There were plenary sessions on the management of asthma, anaphylaxis, and rhinitis, and workshops that dealt with each of these fields in depth. In addition, a number of sessions were devoted to the management of anaphylaxis, food allergy, urticaria, angioedema, and atopic dermatitis. There were research reports and clinical trials of antihistamines, corticosteroids, beta-adrenergic agents, leukotriene antagonists, and combination agents. For example, there were over 20 reported trials on inhaled corticosteroids either for rhinitis or asthma, and a similar amount presented regarding antihistamine therapy, antileukotriene therapy, and beta-adrenergic therapy. Emphasis was placed on the utilization of combination agents specifically montelukast (Merck) and loratadine (Schering-Plough) for the treatment of rhinitis, and formoterol/budesonide (AstraZeneca) and salmeterol/fluticasone (GlaxoSmithKline) for the therapy of asthma. Meetings were held from early morning (6.30) until the late evening (22.00).